Format

Send to

Choose Destination
Pharmaceuticals (Basel). 2019 Jun 19;12(2). pii: E92. doi: 10.3390/ph12020092.

CDK8-Novel Therapeutic Opportunities.

Author information

1
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, 1210 Vienna, Austria. Ingeborg.menzl@vetmeduni.ac.at.
2
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, 1210 Vienna, Austria. Agnieszka.Witalisz-Siepracka@vetmeduni.ac.at.
3
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, 1210 Vienna, Austria. veronika.sexl@vetmeduni.ac.at.

Abstract

Improvements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues.

KEYWORDS:

CDK8; cancer; mediator complex

PMID:
31248103
DOI:
10.3390/ph12020092
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center